Anlotinib Hydrochloride Combined with Bemotuzumab and Nab-Paclitaxel for Immune Checkpoint Inhibitor-Resistant Advanced Biliary Tract Cancer: An Exploratory Study

Authors
Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2026
This article has no abstract
Epistemonikos ID: 169fed9ce0246c25f0488d8c8fe88ba285a85a51
First added on: Sep 12, 2026